CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
Phase 1
Completed
- Conditions
- Interventions
- Drug: Pioglitazone 15mg TabletDrug: CORT125281, 40mg, fastedDrug: Prednisone 25mg, fedDrug: Placebo oral capsule, fedDrug: CORT125281, 360mg, fastedDrug: CORT125281, 240mgDrug: Prednisone 25mg, fastedDrug: Placebo oral capsule, fastedDrug: CORT125281, 120mg, fastedDrug: CORT125281, 720mg, fastedDrug: CORT125281, 360mgDrug: CORT125281, 120mgDrug: CORT125281, 180mgDrug: Placebo oral capsuleDrug: CORT125281, 360mg, fed
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT03335956
- Locations
- ๐ฌ๐ง
Hammersmith Medicines Research, London, United Kingdom
First-in-human Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- Drug: CORT118335, 25 mgDrug: Placebo oral capsuleDrug: CORT118335, 75mgDrug: CORT118335, 225mgDrug: CORT118335, 675mgDrug: CORT118335, 600mgDrug: Prednisone Oral TabletDrug: CORT118335, 375mgDrug: CORT118335, 100mgDrug: Placebo oral suspensionDrug: CORT118335, 300mgDrug: CORT118335, 900mgDrug: CORT118335, 1500mgDrug: CORT118335, 150mgDrug: CORT118335, dose to be determinedDrug: GlucoseDrug: CORT118335, 630mg
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 143
- Registration Number
- NCT03315338
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03259542
- Locations
- ๐บ๐ธ
SeaView Research, Miami, Florida, United States
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT03258372
- Locations
- ๐บ๐ธ
SeaView Reserch, Miami, Florida, United States
A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT03067376
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
Completed
- Conditions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT02922257
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT02804750
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT02762981
- Locations
- ๐บ๐ธ
014, San Francisco, California, United States
๐บ๐ธ038, Scottsdale, Arizona, United States
๐บ๐ธ001, Chicago, Illinois, United States
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Completed
- Conditions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT02663609
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT02014337
- Locations
- ๐บ๐ธ
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
๐บ๐ธRita Nanda, MD, Chicago, Illinois, United States
๐บ๐ธTexas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath